Novo Nordisk A/S Release: Liraglutide Phase 2 Study Shows Increased Insulin Secretion And Improved Blood Glucose Control In People With Type 2 Diabetes

WASHINGTON, June 13 /PRNewswire/ -- Liraglutide, an investigational treatment for type 2 diabetes under development by Novo Nordisk, improved the ability of pancreatic beta cells to secrete insulin in people with type 2 diabetes, according to findings from a late-breaking presentation today at the 66th annual meeting of the American Diabetes Association (ADA).(1)